Showing results (1-10 of 27) with videos related to
Sort By:
Pageof 3
Annual Review of Plant Physiology and Plant Molecular Biology|June 1, 1996
THE FUNCTIONS AND REGULATION OF GLUTATHIONE S-TRANSFERASES IN PLANTSKathleen A. MarrsBest Practice & Research. Clinical Gastroenterology|August 1, 2018
Can we move directly from 5-ASA to a biologic agent in ulcerative colitis?Pieter Hindryckx, Gregor NovakScandinavian Journal of Gastroenterology|December 8, 2025
High persistence and efficacy of ustekinumab as a first-line biological therapy in inflammatory bowel disease: a real-world cohort studyŽiva Šubic, David Drobne, Gregor NovakExpert Review of Gastroenterology & Hepatology|January 19, 2017
Disease-related and drug-induced skin manifestations in inflammatory bowel diseasePieter Hindryckx, Gregor Novak, Antonio Costanzo, et al.European Journal of Gastroenterology & Hepatology|March 11, 2026
Applicator preferences for subcutaneous biologics in inflammatory bowel disease: influence on patient satisfaction and willingness to switch treatmentDušica Prodanova, Ana Janeva, David Drobne, et al.Zebrafish|February 2, 2016
Using Zebrafish to Implement a Course-Based Undergraduate Research Experience to Study Teratogenesis in Two Biology Laboratory CoursesSwapnalee Sarmah, Grady W Chism, Martin A Vaughan, et al.Expert Opinion on Drug Safety|March 10, 2017
The safety of vedolizumab for the treatment of ulcerative colitisGregor Novak, Pieter Hindryckx, Reena Khanna, et al.Clinical Pharmacology and Therapeutics|July 13, 2017
Infection Risk With Biologic Therapy in Patients With Inflammatory Bowel DiseasePieter Hindryckx, Gregor Novak, Stefanos Bonovas, et al.European Journal of Gastroenterology & Hepatology|February 19, 2025
First-line anti-TNF agents, ustekinumab and vedolizumab perform similarly in Crohn' disease, but not in ulcerative colitisEva Supovec, Jurij Hanžel, Gregor Novak, et al.Medicina (Kaunas, Lithuania)|February 24, 2024
Remission Is Maintained after Switch from Dose-Optimised Intravenous Treatment to Subcutaneous Treatment with Vedolizumab in Inflammatory Bowel DiseaseŠpela Pintar, Jurij Hanžel, David Drobne, et al.Pageof 3